Carcinoma a cellule di Merkel

Translated title of the contribution: Merkel cell carcinoma

G. Viola, P. Visca, S. Bucher, E. Migliano, Massimo Lopez

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Merkel cell carcinoma is a rare form of skin cancer of likely neuroendocrine origin wich affects mainly white population in sun-exposed areas. It is an aggressive tumor and survival is dependent on stage at the time of diagnosis. The staging evaluation include CT imaging and recently PET scan. Surgical excision with or without lymph node dissection, followed by postoperative radiotherapy in stage II disease, is the standard treatment of non metastatic disease. The role of adjuvant chemotherapy is still controversial. In patients with metastatic disease, chemotherapy regimens active in small cell lung cancer are generally used. The combination of cyclophosphamide, doxorubicin and vincristine (CAV) has an overall response rate of 75%, whereas the response rate of etoposide in combination with cisplatin or carboplatin is 60%. Experience with other therapeutic agents, such as tumor necrosis factor, interferon and octreotide is scanty. Recently, encouraging preliminary results with targeted agents have been reported. Our experience in 14 patients, four of whom treated with chemotherapy for advanced disease, is in agreement with literature data.

Original languageItalian
Pages (from-to)553-559
Number of pages7
JournalClinica Terapeutica
Volume157
Issue number6
Publication statusPublished - Nov 2006

Fingerprint

Merkel Cell Carcinoma
Drug Therapy
Octreotide
Carboplatin
Small Cell Lung Carcinoma
Vincristine
Skin Neoplasms
Solar System
Etoposide
Adjuvant Chemotherapy
Lymph Node Excision
Positron-Emission Tomography
Doxorubicin
Cyclophosphamide
Interferons
Cisplatin
Radiotherapy
Tumor Necrosis Factor-alpha
Survival
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Viola, G., Visca, P., Bucher, S., Migliano, E., & Lopez, M. (2006). Carcinoma a cellule di Merkel. Clinica Terapeutica, 157(6), 553-559.

Carcinoma a cellule di Merkel. / Viola, G.; Visca, P.; Bucher, S.; Migliano, E.; Lopez, Massimo.

In: Clinica Terapeutica, Vol. 157, No. 6, 11.2006, p. 553-559.

Research output: Contribution to journalArticle

Viola, G, Visca, P, Bucher, S, Migliano, E & Lopez, M 2006, 'Carcinoma a cellule di Merkel', Clinica Terapeutica, vol. 157, no. 6, pp. 553-559.
Viola G, Visca P, Bucher S, Migliano E, Lopez M. Carcinoma a cellule di Merkel. Clinica Terapeutica. 2006 Nov;157(6):553-559.
Viola, G. ; Visca, P. ; Bucher, S. ; Migliano, E. ; Lopez, Massimo. / Carcinoma a cellule di Merkel. In: Clinica Terapeutica. 2006 ; Vol. 157, No. 6. pp. 553-559.
@article{ba5a072e74684e1da1ab730e68d78e46,
title = "Carcinoma a cellule di Merkel",
abstract = "Merkel cell carcinoma is a rare form of skin cancer of likely neuroendocrine origin wich affects mainly white population in sun-exposed areas. It is an aggressive tumor and survival is dependent on stage at the time of diagnosis. The staging evaluation include CT imaging and recently PET scan. Surgical excision with or without lymph node dissection, followed by postoperative radiotherapy in stage II disease, is the standard treatment of non metastatic disease. The role of adjuvant chemotherapy is still controversial. In patients with metastatic disease, chemotherapy regimens active in small cell lung cancer are generally used. The combination of cyclophosphamide, doxorubicin and vincristine (CAV) has an overall response rate of 75{\%}, whereas the response rate of etoposide in combination with cisplatin or carboplatin is 60{\%}. Experience with other therapeutic agents, such as tumor necrosis factor, interferon and octreotide is scanty. Recently, encouraging preliminary results with targeted agents have been reported. Our experience in 14 patients, four of whom treated with chemotherapy for advanced disease, is in agreement with literature data.",
keywords = "Biologic therapy, Chemotherapy, Merkel cell carcinoma",
author = "G. Viola and P. Visca and S. Bucher and E. Migliano and Massimo Lopez",
year = "2006",
month = "11",
language = "Italian",
volume = "157",
pages = "553--559",
journal = "Clinica Terapeutica",
issn = "0009-9074",
publisher = "Societa Editrice Universo",
number = "6",

}

TY - JOUR

T1 - Carcinoma a cellule di Merkel

AU - Viola, G.

AU - Visca, P.

AU - Bucher, S.

AU - Migliano, E.

AU - Lopez, Massimo

PY - 2006/11

Y1 - 2006/11

N2 - Merkel cell carcinoma is a rare form of skin cancer of likely neuroendocrine origin wich affects mainly white population in sun-exposed areas. It is an aggressive tumor and survival is dependent on stage at the time of diagnosis. The staging evaluation include CT imaging and recently PET scan. Surgical excision with or without lymph node dissection, followed by postoperative radiotherapy in stage II disease, is the standard treatment of non metastatic disease. The role of adjuvant chemotherapy is still controversial. In patients with metastatic disease, chemotherapy regimens active in small cell lung cancer are generally used. The combination of cyclophosphamide, doxorubicin and vincristine (CAV) has an overall response rate of 75%, whereas the response rate of etoposide in combination with cisplatin or carboplatin is 60%. Experience with other therapeutic agents, such as tumor necrosis factor, interferon and octreotide is scanty. Recently, encouraging preliminary results with targeted agents have been reported. Our experience in 14 patients, four of whom treated with chemotherapy for advanced disease, is in agreement with literature data.

AB - Merkel cell carcinoma is a rare form of skin cancer of likely neuroendocrine origin wich affects mainly white population in sun-exposed areas. It is an aggressive tumor and survival is dependent on stage at the time of diagnosis. The staging evaluation include CT imaging and recently PET scan. Surgical excision with or without lymph node dissection, followed by postoperative radiotherapy in stage II disease, is the standard treatment of non metastatic disease. The role of adjuvant chemotherapy is still controversial. In patients with metastatic disease, chemotherapy regimens active in small cell lung cancer are generally used. The combination of cyclophosphamide, doxorubicin and vincristine (CAV) has an overall response rate of 75%, whereas the response rate of etoposide in combination with cisplatin or carboplatin is 60%. Experience with other therapeutic agents, such as tumor necrosis factor, interferon and octreotide is scanty. Recently, encouraging preliminary results with targeted agents have been reported. Our experience in 14 patients, four of whom treated with chemotherapy for advanced disease, is in agreement with literature data.

KW - Biologic therapy

KW - Chemotherapy

KW - Merkel cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=33845946564&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845946564&partnerID=8YFLogxK

M3 - Articolo

VL - 157

SP - 553

EP - 559

JO - Clinica Terapeutica

JF - Clinica Terapeutica

SN - 0009-9074

IS - 6

ER -